These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9624234)
21. Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials. Jia WD; Zhang CH; Xu GL; Ge YS; Wang W Hepatogastroenterology; 2010; 57(98):292-9. PubMed ID: 20583430 [TBL] [Abstract][Full Text] [Related]
28. Variant liver estrogen and response to tamoxifen. Villa E; Camellini L; Dugani A; Buttafoco P; Grottola A; Manenti F Gastroenterology; 1996 Jul; 111(1):271-2. PubMed ID: 8698219 [No Abstract] [Full Text] [Related]
29. The nature of tamoxifen action in the control of female breast cancer. Kodama M; Kodama T In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224 [TBL] [Abstract][Full Text] [Related]
30. Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. Rajasekaran D; Elavarasan J; Sivalingam M; Ganapathy E; Kumar A; Kalpana K; Sakthisekaran D Mol Med Rep; 2011; 4(6):1211-7. PubMed ID: 21850372 [TBL] [Abstract][Full Text] [Related]
31. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma. Chow PK Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294 [No Abstract] [Full Text] [Related]
32. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V; Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241 [TBL] [Abstract][Full Text] [Related]
33. Phase II study of flutamide in the treatment of hepatocellular carcinoma. Chao Y; Chan WK; Huang YS; Teng HC; Wang SS; Lui WY; Whang-Peng J; Lee SD Cancer; 1996 Feb; 77(4):635-9. PubMed ID: 8616754 [TBL] [Abstract][Full Text] [Related]
34. The use of endocrine therapy. Pritchard KI; Sutherland DJ Hematol Oncol Clin North Am; 1989 Dec; 3(4):765-805. PubMed ID: 2481670 [TBL] [Abstract][Full Text] [Related]
35. Relation between sex hormones and hepatocellular carcinoma. El Mahdy Korah T; Abd Elfatah Badr E; Mohamed Emara M; Ahmed Samy Kohla M; Gamal Saad Michael G Andrologia; 2016 Nov; 48(9):948-955. PubMed ID: 26791111 [TBL] [Abstract][Full Text] [Related]
36. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Nowak AK; Stockler MR; Chow PK; Findlay M Cancer; 2005 Apr; 103(7):1408-14. PubMed ID: 15744746 [TBL] [Abstract][Full Text] [Related]
37. [Systemic treatment for hepatocellular carcinoma]. Spangenberg HC; Zuber-Jerger I; Thimme R; Blum HE; Von Weizsäcker F Zentralbl Chir; 2003 Nov; 128(11):906-10. PubMed ID: 14669110 [TBL] [Abstract][Full Text] [Related]
38. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Abdel-Rahman O; Lamarca A; Valle JW; Hubner RA Endocr Relat Cancer; 2014; 21(6):R485-93. PubMed ID: 25336571 [TBL] [Abstract][Full Text] [Related]
39. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience. Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583 [TBL] [Abstract][Full Text] [Related]
40. Complete regression of advanced HCC with long acting octreotide. Siveke JT; Herberhold C; Folwaczny C Gut; 2003 Oct; 52(10):1531. PubMed ID: 12970151 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]